Conditions: Hereditary Angioedema (HAE)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 91
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.

Detailed description:

Arms:
arm 1: DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections. arm 2: Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.

Interventions: intervention 1: ecallantide intervention 2: Phosphate Buffer Saline (PBS),
Intervention descriptions: intervention 1: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections. intervention 2: given as three 1mL subcutaneous injections.

Protocol document: